Adverse Events Assessment of adverse events will include the ty pe, incidence, severity (graded by the NCI CTCAE version 5.0) timing, seriousness, and relatedness. 7.1.3. Laboratory Safety Assessment Hematology and blood chemistry will be drawn at the time points described in the Schedule of Activities and anal yzed at local laboratories. Table 13. Safety Laboratory Tests Hem atology Chemistry Coagulation Urinalysis Pregnancy Test Hem oglobin ALT PT or INR Urine dipstick for urine protein: If positive collect 24 -hr and microscopic (Reflex Testing)For female participants of childbearing potential, serum or urine (see Section 7.1.1 )Platelets AST PTT WBC Alk Phos Absolute Neutrophils Sodium Absolute Lymphocytes Potassium Absolute Monocytes Magnesium Urine dipstick for urine blood: If positive collect a microscopic (Reflex Testing)Absolute Eosinophils Total Chloride Absolute Basophils Total calcium Total bilirubin1 BUN or Urea Creatinine Viral Tests2(at Screening) Uric Acid Hepatitis B surface antigen2 Glucose (nonfasted) Hepatitis B core antibody2 Albumin Hepatitis C antibody2 Phosphorous or PhosphateHuman immunodefiency virus (HIV)2 Lactate dehydrogenase Lipase Amylase Bicarbonate or carbon dioxide Total protein TSH + reflex free T4 and free T3 PF-06936308 C3621001 Final Protocol Amendment 2, 22 Dec 2020 PFIZER CONFIDENTIAL Page 93Table 13. Safety Laboratory Tests Hem atology Chemistry Coagulation Urinalysis Pregnancy Test 1.For potential Hy’s Law cases, in addition to repeating AST and ALT, laboratory tests should include albumin, creatine kinase, total bilirubin, direct and indirect bilirubin, gamma -glutamyl transferase, prothrombin time (PT)/INR, alkaline phosphatase, total bile acids and ace taminophen drug and/or protein adduct levels. 2.Hepatitis B surface antigen, hepatitis B core antibody, hepatitis C antibody, and human immunodeficiency virus (HIV). Samples will be analyzed locally.